相关实验视频

Updated: Jul 16, 2025

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

在化疗期间,PARP-1通过诱导帕他那托斯 (parthanatos) 来改善白血病结果

Bruktawit Maru¹, Alessandra Messikommer², Linhui Huang¹

¹Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada.

Cell reports. Medicine

|September 8, 2023

概括

这项研究揭示,细胞氨基酸和伊达鲁素化学疗法在急性髓性白血病 (AML) 中触发了被编程的细胞死亡,称为帕尔塔纳托斯. 最佳的PARP-ribose聚合酶1 (PARP-1) 水平提高了化疗的有效性和患者的存活率.

科学领域:

生物化学生物化学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

化学疗法研究传统上侧重于细胞亡.
治疗急性髓性白血病 (AML) 的疗效可能会有很大差异.
了解替代细胞死亡途径对于改善癌症治疗至关重要.

研究的目的:

为了研究在AML化疗中PARP-1介导的聚ADP-ribose) 聚合酶1 (PARP-1) 中程细胞死亡 (parthanatos) 的作用.
为了确定帕萨纳托斯诱导对患者存活率的影响.
探索PARP-1水平和AML中的药物敏感性之间的关系.

主要方法:

用cytarabine和idarubicin治疗AML细胞系,健康的供体PBMC和患者衍生的AML细胞.
评估帕尔塔纳托斯诱导及其与细胞死亡的相关性.
基于帕萨纳托斯阳性的患者生存数据的分析.
操纵PARP-1活性 (过度表达,抑制,基底水平) 和评估药物敏感性.
检查RNA表达数据库的PARP-1水平相关性.

主要成果:

在AML样本和细胞系的子集中,cytarabine和idarubicin诱导了甲状腺炎.
帕他那托斯阳性AML患者的生存率提高了3倍.
基础PARP-1水平与与过度表达或抑制相比,对化疗的敏感性更高有关.
RNA表达数据支持了最佳PARP-1水平和良好的治疗反应之间的相关性.

结论:

用细胞氨基酸和伊达鲁比辛进行化疗可以诱导帕尔塔纳托斯,AML的一个独特的编程细胞死亡途径.
PARP-1 在调解甲状腺炎和影响化疗结果方面发挥着关键作用.
保持最佳的PARP-1水平对于最大限度地提高化疗反应和改善AML患者的存活率至关重要.

关键词:

在NAD+ADP-ribosyltransferase1中在 PAR PAR PAR 里面.在PARP-1中.急性骨髓单细胞和单细胞白血病.灭症 (apoptosis) 是一种死亡的过程.癌症生物学癌症生物学独立于caspase的编程细胞死亡.核酸类比的核酸类比聚乙烯 (ADP-ribose) 是一种聚乙烯的组成部分.精准医学是一门精准医学.预后性血液测试血液测试预后性血液测试

更多相关视频

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...